| 000 | 01492 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250515072809.0 | ||
| 264 | 0 | _c20080324 | |
| 008 | 200803s 0 0 eng d | ||
| 022 | _a1472-4146 | ||
| 024 | 7 |
_a10.1136/jcp.2007.049460 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBrunner, A | |
| 245 | 0 | 0 |
_aEpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder. _h[electronic resource] |
| 260 |
_bJournal of clinical pathology _cMar 2008 |
||
| 300 |
_a307-10 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntigens, Neoplasm _xanalysis |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xanalysis |
| 650 | 0 | 4 |
_aCarcinoma, Transitional Cell _xchemistry |
| 650 | 0 | 4 |
_aCell Adhesion Molecules _xanalysis |
| 650 | 0 | 4 | _aEpithelial Cell Adhesion Molecule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunohistochemistry |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aNeoplasm Invasiveness |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 |
_aRisk Assessment _xmethods |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 |
_aUrinary Bladder Neoplasms _xchemistry |
| 700 | 1 | _aPrelog, M | |
| 700 | 1 | _aVerdorfer, I | |
| 700 | 1 | _aTzankov, A | |
| 700 | 1 | _aMikuz, G | |
| 700 | 1 | _aEnsinger, C | |
| 773 | 0 |
_tJournal of clinical pathology _gvol. 61 _gno. 3 _gp. 307-10 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1136/jcp.2007.049460 _zAvailable from publisher's website |
| 999 |
_c17123911 _d17123911 |
||